Interferon-induced protein 44-like (IFI44L)

Interferon-induced protein 44-like (IFI44L) is a cytoplasmic protein of 452 amino acids encoded by the IFI44L gene on chromosome 1p31.1[1][6]. It is a member of the IFI44 family of interferon-stimulated genes (ISGs) and is robustly upregulated by type I interferons during the innate immune response[3][6]. IFI44L exerts antiproliferative and pro-apoptotic effects in various cell types, notably in cancer and immune cell populations, and is involved in direct antiviral defense against a variety of viral pathogens[1][4]. Mechanistically, IFI44L participates in modulating IFN pathways through interactions with signaling proteins such as FKBP5, impacting key kinases (IKKε, IKKβ) and downstream immune modulators (IRF-3, IκBα)[4]. IFI44L is highly responsive to epigenetic regulation (notably DNA methylation), and its expression correlates with disease states such as systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis, and various cancers[1][5]. Its methylation status and expression levels serve as diagnostic and prognostic biomarkers, particularly for autoimmune disease activity and infection discrimination[5][2]. IFI44L has been proposed as a candidate therapeutic target due to its capacity to regulate IFN signaling, pro-apoptotic anti-tumor activity, and contribution to pathogen defense, although no drugs are known to directly target IFI44L as of now[1][4][5].

Other names

C1orf29GS3686TLDC5B

Antiviral, antiproliferative, and pro-apoptotic effects via induction by interferons; downstream modulation of immune signaling pathways including JAK/STAT; negative feedback regulation of IFN signaling (through binding to FKBP5 and inhibition of IKKε/IKKβ kinase activity, reducing IRF-3 and IκBα phosphorylation)[4][1]